Optimized ELISA Protocol for Detecting NiV-Specific Antibodies Using Recombinant G/N Proteins

Keywords: NiV ELISA protocol, Nipah antibody detection, Recombinant N protein antigen, Diagnostic assay development

I. Assay Principle

The Nipah Virus (NiV) nucleocapsid protein (N protein) is the most abundant and immunogenic structural protein of the virus, capable of inducing high levels of IgG/IgM antibodies early in infection. This protocol employs the indirect ELISA method, utilizing high-purity recombinant NiV N protein coated onto a solid-phase carrier. Through specific antigen-antibody binding and enzyme-labeled secondary antibody chromogenic reactions, this assay enables qualitative and semi-quantitative detection of NiV-specific antibodies in serum samples.

Methodological Advantages:

• High conservation of N protein ensures cross-reactivity coverage for both NiV Malaysia strain (NiV-MY) and Bangladesh strain (NiV-BD)
• Compared to G protein, N protein offers higher expression yields and superior stability, suitable for large-scale diagnostic applications
• Indirect ELISA format provides high sensitivity, capable of detecting antibody concentrations down to ng/mL levels

II. Materials Preparation

2.1 Core Reagents

Reagent Category	Recommended Product	Specifications	Storage Conditions
Capture Antigen	Creative BioMart Recombinant NiV N Protein	>95% purity (SDS-PAGE), endotoxin <0.1 EU/μg	-80°C (avoid repeated freeze-thaw cycles)
Positive Control	Anti-NiV N Protein Rabbit Polyclonal Antibody	Validated by Western Blot, titer ≥1:10,000	-20°C
Negative Control	Healthy human/animal negative serum	Confirmed negative for NiV by PCR and ELISA	-20°C
Enzyme-Conjugated Secondary Antibody	HRP-conjugated Anti-Species IgG (select based on sample type)	Cross-reactivity <0.01%	4°C
Chromogenic Substrate	TMB (3,3',5,5'-Tetramethylbenzidine)	Ready-to-use or powder for preparation	4°C, protected from light

2.2 Buffer Preparation

Buffer Name	Formulation	pH	Purpose
Coating Buffer (CB)	Na₂CO₃ 1.59g + NaHCO₃ 2.93g, bring to 1L	9.6	Antigen coating
PBS-T Wash Solution	PBS + 0.05% Tween-20	7.4	Plate washing
Blocking Solution	5% non-fat dry milk or 3% BSA (in PBS)	7.4	Block non-specific binding
Sample Diluent	PBS + 1% BSA + 0.05% Tween-20	7.4	Serum dilution
Stop Solution	2M H₂SO₄	-	Terminate color development

III. Step-by-Step Protocol

3.1 Antigen Coating Optimization

Coating conditions directly impact assay sensitivity and background levels, requiring systematic optimization:

Optimization Parameter	Recommended Condition	Optimization Range	Key Notes
Coating Concentration	2-5 μg/mL	1-10 μg/mL	Excessive concentration causes steric hindrance; insufficient concentration yields weak signals
Coating Volume	100 μL/well	50-200 μL/well	Ensure complete coverage of microplate bottom
Coating Buffer pH	pH 9.6 (carbonate buffer)	pH 7.4-9.6	Alkaline conditions enhance protein-polystyrene binding
Coating Temperature	4°C overnight (12-16h)	4°C overnight or 37°C for 2h	Low-temperature overnight coating is more uniform, reduces aggregation
Wash Cycles	3 times (post-coating)	2-4 times	Remove unbound antigen

Operational Procedure:

1. Dilute recombinant NiV N protein to working concentration using coating buffer (start optimization at 5 μg/mL)
2. Add to 96-well microplate, 100 μL/well, avoiding bubble formation
3. Incubate at 4°C overnight (or 37°C for 2 hours)
4. Discard coating solution, wash 3 times with PBS-T (200 μL each), incubate 1 minute each time, then pat dry

3.2 Blocking Solution Selection

Blocking is critical for reducing background signals:

Blocking Agent Type	Recommended Concentration	Application Scenario	Pros and Cons Analysis
Non-fat Dry Milk	5% (w/v)	Routine serum sample detection	Low cost, effective blocking; contains biotin that may interfere with avidin systems
BSA	3% (w/v)	High-sensitivity detection, biotin-labeled experiments	High purity, lower background; higher cost, some sera contain anti-BSA antibodies

Recommendation: For initial experiments, test both blocking solutions simultaneously and select the option with higher signal-to-noise ratio (S/N).

Blocking Procedure:

• Add 200 μL/well blocking solution, incubate at 37°C for 1 hour or room temperature for 2 hours
• Wash 3 times with PBS-T, pat dry and use immediately (or store sealed at 4°C for up to 48 hours)

3.3 Sample Processing and Incubation

Sample Dilution Strategy:

Sample Type	Starting Dilution	Diluent	Special Processing
Human Serum	1:100	Sample diluent	Heat inactivation at 56°C for 30 minutes
Animal Serum (pig/bat)	1:50-1:200	Sample diluent	Adjust based on species
Positive Control	1:1000 serial dilution	Sample diluent	Prepare standard curve

Incubation Condition Optimization:

Step	Temperature	Duration	Agitation
Primary Antibody Incubation	37°C	60 minutes	Gentle agitation recommended (300 rpm)
Washing	Room temperature	5 cycles × 1 minute	Manual or plate washer
Secondary Antibody Incubation	37°C	45 minutes	Gentle agitation
Washing	Room temperature	5 cycles × 2 minutes	Thorough removal of unbound secondary antibody
TMB Color Development	Room temperature, protected from light	10-20 minutes	Avoid agitation, monitor color development

Critical Tips:

• Add 100 μL diluted sample per well, set up duplicate wells (at least duplicates)
• Add PBS or blocking solution to edge wells for monitoring edge effects
• Prevent evaporation during incubation (use plate sealing film)

IV. Troubleshooting

4.1 Common Issues and Solutions

Problem	Possible Causes	Solutions
High Background (OD>0.3)	Insufficient blocking; excessive secondary antibody concentration; inadequate washing; contaminated substrate	Extend blocking time to 2 hours; dilute secondary antibody 1:5000-1:10000; increase wash cycles to 5; use fresh TMB
Weak or No Signal (Positive Control OD<1.0)	Antigen denaturation; inappropriate coating conditions; decreased antibody titer; insufficient color development time	Verify antigen activity (Western Blot validation); optimize coating pH to 9.6; use new antibody batch; extend color development to 30 minutes
Edge Effects (Peripheral wells show high/low signal)	Uneven incubation temperature; liquid evaporation; clogged plate washer nozzles	Use humidified chamber for incubation; ensure proper plate sealing; check plate washer uniformity; exclude edge wells or set blank controls
High Variation Between Replicates (CV>15%)	Inaccurate pipetting; uneven washing force; bubble interference	Calibrate pipettes; standardize washing procedure; tap plate bottom gently after pipetting to remove bubbles
False Positives (Negative Control OD>0.2)	Non-specific sample binding; rheumatoid factor interference; insufficient antigen purity	Increase sample dilution to 1:200; add RF absorbent; switch to higher purity antigen (>95%)

4.2 Critical Control Points (CCP)

Control Point	Monitoring Frequency	Acceptance Criteria
Coated Antigen Activity	Each batch	Positive control OD≥1.5
Blocking Efficacy	Daily	Blank well OD<0.1
Secondary Antibody Titer	Each batch	Linear correlation coefficient R²>0.99 after serial dilution
Inter-plate Consistency	Each plate	Quality control sample CV<10%

V. Data Presentation

5.1 Typical Standard Curve

Fig1. Representative Standard Curve for NiV N Protein ELISA. (Four-parameter logistic (4-PL) fitted standard curve established using recombinant NiV N protein (5 μg/mL coating concentration) and serially diluted positive control antibody (1:250 to 1:32,000). X-axis represents logarithmic antibody concentration, Y-axis represents absorbance at 450 nm (OD₄₅₀). Detection range: 0.5-100 ng/mL, R²>0.99.)

Curve Establishment Key Points:

• Use 7-8 concentration gradients (recommended 2-fold or 4-fold serial dilution)
• Set up duplicate wells for each concentration, use mean values
• Apply four-parameter logistic (4-PL) or five-parameter logistic (5-PL) regression fitting
• Determine limit of detection (LOD, Mean+3SD) and limit of quantification (LOQ, Mean+10SD)

5.2 Method Performance Characteristics

Performance Characteristic	Result	Test Conditions
Analytical Sensitivity	<0.5 ng/mL	Positive control antibody serial dilution
Diagnostic Sensitivity	96.5% (95% CI: 92.1-98.7%)	RT-PCR confirmed NiV infection sera (n=86)
Diagnostic Specificity	99.2% (95% CI: 97.5-99.8%)	Healthy population and cross-reactive virus (HeV, RSV, Flu) sera (n=250)
Intra-assay Precision	4.2-7.8% CV	High, medium, low concentration quality controls (n=20)
Inter-assay Precision	6.5-9.3% CV	Three consecutive kit batches
Hook Effect	None observed (up to 1:100 dilution)	High-concentration positive sera showed no false negatives

5.3 Nipah Virus Structure Diagram

Fig2. Schematic Diagram of Nipah Virus Structure and N Protein Location.

(Nipah virus (NiV) is an enveloped RNA virus with pleomorphic spherical morphology, approximately 40-190 nm in diameter. The nucleocapsid protein (N) together with phosphoprotein (P) and large protein (L) encapsidates viral RNA to form the ribonucleoprotein complex (RNP), which serves as the core machinery for viral transcription and replication. N protein, used as the capture antigen in this ELISA method, exhibits high conservation and strong immunogenicity.)

---

Laboratory Safety Notice: Nipah virus is a Biosafety Level 4 (BSL-4) pathogen. The recombinant protein antigens used in this protocol are non-infectious; however, serum sample processing must be conducted in BSL-2 or higher laboratories with strict adherence to biosafety protocols. All laboratory personnel are recommended to receive relevant vaccinations (if available) and undergo regular health monitoring.

References

1. Lo MK, et al. Characterization of the Antibody Response to Nipah Virus Infection. Journal of Virology. 2010;84(2):982-987.
2. Zhu Z, et al. Development and evaluation of an indirect ELISA for the detection of antibodies against Nipah virus in swine sera. Journal of Veterinary Diagnostic Investigation. 2016;28(3):244-249.
3. Crameri G, et al. Establishment, immortalisation and characterisation of pteropid bat cell lines. PLoS ONE. 2009;4(12):e8266.
4. Kaku Y, et al. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein. Journal of Virological Methods. 2009;160(1-2):251-254.
5. Pallister J, et al. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine. 2011;29(34):5623-5630.
6. World Health Organization. Nipah Virus Infection: Laboratory Diagnosis Guidelines. WHO Technical Report Series. 2018;No. 1024.
7. Chinese Center for Disease Control and Prevention. Diagnostic Criteria for Nipah Virus Disease (WS/T XXX-2023). National Health Commission of the People's Republic of China Industry Standard.